The Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 154 participants.
Also called NCT04706429
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 154 participants
- Sponsor
- Registry
-
NCT04706429 -
2020-002242-17 -
ISRCTN57145331
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT04706429. Randomized; quadruple masking; primary purpose treatment. Start 2020-12-01 (actual); primary completion 2024-04-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Efficacy and Mechanism of Trientine in Patients With Hypertrophic Cardiomyopathy
- Acronym
- TEMPEST
- Condition
- Hypertrophic Cardiomyopathy
- Intervention (Drug)
- Trientine
- Intervention (Drug)
- Placebo
- Lead sponsor
- Manchester University NHS Foundation Trust
- Collaborator
- National Institute for Health Research, United Kingdom
- Collaborator
- University of Manchester
- Collaborator
- University of Liverpool
- Collaborator
- Univar BV
- Collaborator
- University of Oxford
Record details
- Record id
cardio:ct-nct04706429- Content hash
9f346432ce1fb180d5aaf2cfd8558f1b426ce11bffe01200b5d14b0e0eefee18